Most Popular News Stories on OBR Daily
(Wall Street Journal) May 29, 2018 - Amid health care tailored to an individual’s DNA, do massive clinical trials that take years and involve thousands of patients still matter?
(Forbes) June 7, 2018 - At the recently concluded annual meeting of the American Society of Clinical Oncology (ASCO) a group of researchers from Mexico City described a surprising discovery: In a phase 2 trial in patients with stage 4 lung cancer, a 24-year-old diabetes drug significantly improved survival when added to a standard therapy.
(Reuters) May 23, 2018 - Merck & Co on Wednesday said its cancer drug Keytruda helped extend survival and prevented disease progression when tested in a late-stage study in combination with chemotherapy for a type of lung cancer.
(Washington Post) June 5, 2018 - New treatments are expensive and experimental, but they sure seem worth it.
(AstraZeneca) May 25, 2018 - Imfinzi met the second primary endpoint of overall survival which was both statistically-significant and clinically-meaningful at a planned interim analysis.
(COA) May 31, 2018 - The Community Oncology Alliance (COA) has filed a lawsuit in the U.S. District Court for the District of Columbia to stop the United States Department of Health and Human Services (HHS) and the White House Office of Management and Budget (OMB) from applying the Medicare sequester cut to reimbursement for Part B drugs.
(STAT) May 29, 2018 - “It’s possible that we already are at the juncture where patients diagnosed with this disease could live with this disease for the rest of their lives,” according to Dr. Ola Landgren, chief of the Multiple Myeloma Service at Memorial Sloan Kettering Cancer Center in New York.
(MD Anderson) June 16, 2018 - A study led by The University of Texas MD Anderson Cancer Center revealed that the investigational drug quizartinib prolonged overall survival for patients with a deadly form of acute myeloid leukemia (AML) linked to a genetic mutation called FMS-like internal tandem duplications (FLT3-ITD).
(Roche) May 29, 2018 - Roche today announced that the Phase III IMpower130 study met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS).
(MedCity News) June 7, 2018 - Although bluebird bio’s CAR-T cell therapy for multiple myeloma is already in a registration-directed clinical trial, Janssen sees plenty of room to muscle in as well.